Peptic ulcer disease today

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 2, 2006, Pages 80-89

  Yuan, Yuhong ^a   Padol, Ireneusz T ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Duodenal ulcer; Gastric ulcer; Helicobacter pylori; NSAIDs; Peptic ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE; BISMUTH DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CLARITHROMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C19; IMMUNOSUPPRESSIVE AGENT; LANSOPRAZOLE; LICOFELONE; LIPOXYGENASE INHIBITOR; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NITRIC OXIDE; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM CHLORIDE; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR; TETRACYCLINE; UNINDEXED DRUG;

BACTERIUM CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG TOLERABILITY; DUODENUM ULCER; ERADICATION THERAPY; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MONOTHERAPY; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RECURRENT PEPTIC ULCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; STOMACH ACID SECRETION; STOMACH EROSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H1 ANTAGONISTS; HUMANS; PEPTIC ULCER; PROTON PUMPS; RISK FACTORS;

EID: 33645325419     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0393     Document Type: Review

References (74)

1. Gustavsson S and Nyren O (1989) Time trends in peptic ulcer surgery, 1956 to 1986. A nation-wide survey in Sweden. Ann Surg 210: 704-709
2. Sach G (1997) Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17: 22-37
3. Sonnenberg A (1985) Geographic and temporal variations in the occurrence of peptic ulcer disease. Scand J Gastroenterol Suppl 110: 11-24
4. Sonnenberg A and Everhart JE (1996) The prevalence of self-reported peptic ulcer in the United States. Am J Public Health 86: 200-205
5. Sandler RS et al. (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500-1511
6. Yuan Y and Hunt RH (2006) Treatment of non-NSAID and non-H. pylori gastroduodenal ulcers and hypersecretory states. In Therapy of digestive disorders, edn 2, 315-336 (Eds Wolfe MM et al.) London, UK: Elsevier
7. Tummala S et al. (2004) Update on the immunologic basis of Helicobacter pylori gastritis. Curr Opin Gastroenterol 20: 592-597
8. Dore MP and Graham DY (2000) Pathogenesis of duodenal ulcer disease: The rest of the story. Baillieres Best Pract Res Clin Gastroenterol 14: 97-107
9. Laine L (1996) Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 6: 489-504
10. Wolfe MM and Soll AH (1988) The physiology of gastric acid secretion. N Engl J Med 319: 1707-1715
11. Marshall BJ and Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315
12. Marshall BJ et al. (1985) Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 142: 439-444
13. 13C urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis 157: 777-780
14. Xia HH et al. (2001) Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in western Sydney between 1990 and 1998. Dig Dis Sci 46: 2716-2723
15. Perez-Aisa MA et al. (2005) Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 21: 65-72
16. Ford A et al. (2004) Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. The Cochrane Database of Systematic Reviews. Issue 4, Art. No. CD003840.pub2
17. Laine L (2001) Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120: 594-606
18. Weisman SM and Graham DY (2002) Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162: 2197-2202
19. Niv Y et al. (2005) Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 50: 78-80
20. Slattery J et al. (1995) Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 37: 509-511
21. Lanas A et al. (2000) Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343: 834-839
22. Silverstein FE et al. (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255
23. Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528
24. Hunt RH et al. (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 98: 1725-1733
25. Schnitzer TJ et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) reduction in ulcer complications randomised controlled trial. Lancet 364: 665-674
26. Huang JQ et al. (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 359: 14-22
27. Lanas A et al. (2002) Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16: 779-786
28. Talley NJ et al. (2005) American Gastroenterology Association technical review on the evaluation of dyspepsia. Gastroenterology 129: 1756-1780
29. Ford AC et al. (2005) Helicobacter pylori 'test and treat' or endoscopy for managing dyspepsia: An individual patient data meta-analysis. Gastroenterology 128: 1838-1844
30. Vakil N and Vaira D (2004) Non-invasive tests for the diagnosis of infection. Rev Gastroenterol Disord 4: 1-6
31. Perri F et al. (1995) The influence of isolated doses of drugs, feeding and colonic bacterial ureolysis on urea breath test results. Aliment Pharmacol Ther 9: 705-709
32. Prince MI et al. (1999) The CLO test in the UK: Inappropriate reading and missed results. Eur J Gastroenterol Hepatol 11: 1251-1254
33. Bilardi C et al. (2002) Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 16: 1733-1738
34. Malfertheiner P et al. (2002) Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16: 167-180
35. Vallve M et al. (2002) Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: A meta-analysis. Aliment Pharmacol Ther 16: 1149-1156
36. Calvet X et al. (2000) A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 14: 603-609
37. Lahaie RG and Gaudreau C (2000) Helicobacter pylori antibiotic resistance: Trends overtime. Can J Gastroenterol 14: 895-899
38. Laine L (2003) Is it time for quadruple therapy to be first line? Can J Gastroenterol 17 (Suppl B): 33B-35B
39. Gisbert JP and Pajares JM (2002) Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 16: 1047-1057
40. Furuta T et al. (2003) Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol 25: 131-143
41. Padol S et al. (2005) The effect of CYP2C19 polymorphism on H. pylori eradication rates with PPI dual and triple first line therapies - a meta-analysis [abstract #T970]. Gastroenterology 128 (Suppl 2): A430
42. Leodolter A et al. (2001) A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 15: 1949-1958
43. Gisbert JP et al. (2004) H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. The Cochrane Database of Systematic Reviews, Issue 2, Art. No. CD004062.pub2
44. Arkkila PE et al. (2005) Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol 17: 93-101
45. Gisbert JP and Pajares JM (2005) Systematic review and meta-analysis: Is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 21: 795-804
46. Ohara T et al. (2004) Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: Pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI. Hepatogastroenterology 51: 338-342
47. Lai KC et al. (2002) Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346: 2033-2038
48. Yeomans ND (1988) New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. Am J Med 104: 56S-61S
49. Pilotto A et al. (2004) Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 20: 1091-1097
50. Lanas A (2004) Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 20: 321-331
51. Rostom A et al. (2002) Prevention of NSAID-induced gastroduodenal ulcers. The Cochrane Database of Systematic Reviews, Issue 4, Art. No. CD002296.pub2
52. Goldstein JL et al. (2004) Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post hoc subanalysis. Clin Ther 26: 1637-1643
53. Dubois RW et al. (2004) Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclooxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 19: 197-208
54. Chan FK et al. (2004) Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: Results of a randomized double-blind trial. Gastroenterology 127: 1038-1043
55. Hunt RH et al. (2002) Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents. Can J Gastroenterol 16: 231-240
56. Lohmander LS et al. (2005) A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 64: 449-456
57. Fiorucci S et al. (2003) Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. Gastroenterology 124: 600-607
58. Bias P et al. (2004) The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: Results from a randomized, controlled trial. Am J Gastroenterol 99: 611-618
59. Pounder RE (2002) Helicobacter pylori and NSAIDs - the end of the debate? Lancet 359: 3-4
60. Hunt RH and Bazzoli F (2004) Review article: Should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 19 (Suppl 1): 9-16
61. Vergara M et al. (2005) Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21: 1411-1418
62. Chan FK et al. (2005) NSAID-induced peptic ulcers and Helicobacter pylori infection: Implications for patient management. Drug Saf 28: 287-300
63. Pounder RE (2002) Helicobacter pylori and NSAIDs - the end of the debate? Lancet 359: 3-4
64. Giral A et al. (2004) Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. J Gastroenterol Hepatol 19: 773-777
65. Chan FK et al. (2001) Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344: 967-973
66. MacDonald TM et al. (1997) Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: A cohort study. BMJ 315: 1333-1337
67. Quan C and Talley NJ (2002) Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 97: 2950-2961
68. Sprung DJ and Apter MN (1998) What is the role of Helicobacter pylori in peptic ulcer and gastric cancer outside the big cities? J Clin Gastroenterol 26: 60-63
69. Jyotheeswaran S et al. (1998) Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: Is empirical triple therapy justified? Am J Gastroenterol 93: 574-578
70. Nishikawa K et al. (2000) Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 12: 635-640
71. Leontiadis GI et al. (2005) Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 330: 568
72. Bardhan KD (1993) Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 7 (Suppl 1): 13-24
73. Lanas AI et al. (1995) Risk factors associated with refractory peptic ulcers. Gastroenterology 109: 1124-1133
74. Lu H et al. (2005) Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 128: 833-848